OHSU

Charles Keller Lab

Charles Keller Lab

 

The Keller Laboratory studies the driving mechanisms and therapeutic targets in the childhood muscle cancers, alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma, and the childhood brain tumor, medulloblastoma.

Latest from the Keller Lab Blog
 

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma

We hope you will enjoy this review and commentary as much as we do.  A lot of people in pharma, the community-at-large and scientific thought leaders helped to create this somewhat out of the box concept proposal.  With some additional community volunteers, I think we could really put this plan to action.  Sincerely, Charles
  
[ This review was made possible by a gift from the Ethan Jostad Foundation ].
 

Congratulations, Ken!

Ken's paper on sclerosing rhabdomyosarcoma is accepted for publication.  This paper entitled, "MDM2 Amplification and PI3KCA mutation in a Case of Sclerosing Rhabdomyosarcoma" is now available online here.  Co-authors include Dr. Atiya Mansoor, an expert on sarcoma pathology.  We thank Jonathan Hart and Peter Vogt for key reagents for these studies.
 

Congratulations, Stefano!

Congratulations to Stefano Biressi in the Rando laboratory at Stanford on a fabulous lineage study of muscle progenitors accepted by the journal, Developmental Biology.  This paper is entitled, "Myf5 expression during fetal myogenesis defines the developmental progenitors of adult satellite cells" and is available online here.  Co-authors from our lab include alumni member, Koichi Nishijo.